ADMA Biologics (NASDAQ:ADMA – Free Report) had its price target cut by Mizuho from $24.00 to $20.00 in a research note published on Thursday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.
Several other research analysts also recently weighed in on ADMA. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research lowered shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Canaccord Genuity Group assumed coverage on shares of ADMA Biologics in a research report on Monday, April 20th. They set a “buy” rating and a $21.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, ADMA Biologics has an average rating of “Hold” and a consensus price target of $19.00.
Read Our Latest Report on ADMA Biologics
ADMA Biologics Stock Down 2.6%
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 38.94% and a net margin of 32.43%.The firm’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. Research analysts anticipate that ADMA Biologics will post 0.93 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve Elms purchased 7,000 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 3.90% of the company’s stock.
Hedge Funds Weigh In On ADMA Biologics
A number of hedge funds have recently made changes to their positions in ADMA. Lido Advisors LLC boosted its stake in shares of ADMA Biologics by 3.8% in the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 629 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in ADMA Biologics by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 634 shares in the last quarter. Cim LLC boosted its stake in ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after purchasing an additional 665 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after buying an additional 700 shares in the last quarter. Finally, Clearstead Advisors LLC grew its holdings in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.
Trending Headlines about ADMA Biologics
Here are the key news stories impacting ADMA Biologics this week:
- Positive Sentiment: ASCENIV growth and strong profitability: ASCENIV revenue rose ~28% year‑over‑year and helped drive solid margins and EPS improvement. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
- Positive Sentiment: Strong cash generation and adjusted profitability: Q1 adjusted net income and adjusted EBITDA increased year‑over‑year and cash from operations was ~$58M, supporting a healthy balance sheet. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
- Positive Sentiment: EPS growth: GAAP/adjusted metrics showed year‑over‑year EPS improvement (Q1 EPS ~ $0.19 vs $0.11 a year ago), which supports near‑term profitability narrative. ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down (Zacks)
- Neutral Sentiment: Analyst actions: Mizuho trimmed its price target (from $24 to $20) but kept an outperform rating — reflects continued upside belief but reduced near‑term assumptions. Benzinga: Mizuho price target change
- Negative Sentiment: FY2026 guidance cut and withdrawal of long‑term guidance: ADMA updated FY2026 revenue guidance to $530M–$560M (well below Street ~ $625M) and withdrew longer‑term guidance, signaling near‑term market/competitive pressures in the immunoglobulin (IG) market. That outlook revision is a primary driver of the share decline. Adma projects 2026 revenue of $530M-$560M and withdraws longer-term guidance (Seeking Alpha)
- Negative Sentiment: Multiple securities investigations and channel‑stuffing allegations: Several law firms (Lowey Dannenberg, Bleichmar Fonti & Auld, Rosen, Pomerantz, Block & Leviton, Kehoe, etc.) have announced probes into ADMA following reports of channel‑stuffing and alleged misleading statements — this legal overhang amplifies selling pressure and uncertainty. Lowey Dannenberg investigation (GlobeNewswire) BFA investigation / channel‑stuffing claims (GlobeNewswire)
- Negative Sentiment: Large near‑term stock volatility: Media and law‑firm notices highlight a >20% intraday/overnight share drop after the call and guidance cut; increased volatility and potential litigation risk raise execution uncertainty for investors. Shares fall >24% (GlobeNewswire)
ADMA Biologics Company Profile
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Recommended Stories
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
